Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 6 | Molecular Cancer

Figure 6

From: Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin

Figure 6

Combined treatment with TRAIL receptor antibodies and cisplatin increases cell death. H28, ZL5, ZL55 and H226 cells were cultured with or without 2 μM cisplatin for 24 h. Cells were then left untreated or treated with 10 μg/ml Mapatumumab (Mapa) (A) or Lexatumumab (Lexa) (B) for 24 h. Lysates were analyzed by immunoblotting as described under material and methods.

Back to article page